NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events
Item 8.01.Other Events.

On April 17, 2018, NewLink Genetics Corporation issued a press release titled "NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation."

A copy of the press release and the accompanying slides are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

Section9 – Financial Statements and Exhibits

Item 9.01.FinancialStatements and Exhibits.

(d) Exhibits.

NEWLINK GENETICS CORP Exhibit
EX-99.1 2 nlnk-20180417x8kxex991.htm PRESS RELEASE Exhibit Exhibit 99.1NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster PresentationAMES,…
To view the full exhibit click here

About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.